Trusted Resources: Education
Scientific literature and patient education texts
Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study
source: Circulation
year: 2016
authors: Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC
summary/abstract:Background:
Heart failure caused by wild-type transthyretin amyloidosis (ATTRwt) is an underappreciated cause of morbidity and mortality in the aging population. The aims of this study were to examine features of disease and to characterize outcomes in a large ATTRwt cohort.
Methods and results:
Over 20 years, 121 patients with ATTRwt were enrolled in a prospective, observational study. Median age at enrollment was 75.6 years (range, 62.6-87.8 years); 97% of patients were white. The median survival, measured from biopsy diagnosis, was 46.69 months (95% confidence interval, 41.95-56.77); 78% of deaths were attributable to cardiac causes. By Kaplan-Meier analysis, 5-year survival was 35.7% (95% confidence interval, 25-46). Impaired functional capacity (mean Vo2max, 13.5 mL•kg(-1)•min(-1)) and atrial fibrillation (67%) were common clinical features. Multivariate predictors of reduced survival were elevated serum brain natriuretic peptide (482 ± 337 pg/mL) and uric acid (8.2 ± 2.6 mg/dL), decreased left ventricular ejection fraction (50% median; range, 10%-70%), and increased relative wall thickness (0.75 ± 0.19).
Conclusions:
In this series of patients with biopsy-proven ATTRwt, poor functional capacity and atrial arrhythmias were common clinical features. Elevated brain natriuretic peptide and uric acid, decreased left ventricular ejection fraction, and increased relative wall thickness were associated with limited survival of only 35.7% at 5 years for the group as a whole. These data establish the natural history of ATTRwt, provide statistical basis for the design of future interventional clinical trials, and highlight the need for more sensitive diagnostic tests and disease-specific treatments for this disease.
organization: University of Pavia, Italy; Boston University School of Medicine, USA
DOI: 10.1161/CIRCULATIONAHA.115.018852
read more full text
Related Content
-
Treatment for ATTR Cardiomyopathy – ASG Webinar 2/7https://www.youtube.com/watch?v=IzC_yaqs...
-
Financial Assistance Update by Paula Schmitt – ASG Webinar 7.15.23 – 5/7https://www.youtube.com/watch?v=UcxmPgZ7...
-
Q&A Session One with Drs. Lyle, Cheng, Karam – ASG Webinar 7.15.23 – 6/7https://www.youtube.com/watch?v=UcxmPgZ7...
-
Portland — Amyloidosis Support Groups Meeting — LIVE — Saturday, April 20, 2024When: Saturday, April 20, 2024 AL wi...
-
ATTR in the Heart – ASG Webinar 1/7https://www.youtube.com/watch?v=IzC_yaqs...
-
Q&A Discussion on Attralus Trials and Diflunisal Use – ASG Webinar 7.15.23 – 7/7https://www.youtube.com/watch?v=UcxmPgZ7...
-
Transthyretin Cardiac Amyloidosis (ATTR-CM) Signs, Symptoms, and Diagnostic Approach – ASG Webinar 1/11https://www.youtube.com/watch?v=K2TmwAfu...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.